http://www.fpnotebook.com/
Acute Sinusitis Management
Aka: Acute Sinusitis Management, Sinusitis Management, Acute Bacterial Rhinosinusitis- See Also
- Management: General Measures
- Symptomatic relief
- Warm, moist compresses over sinuses
- Tylenol
- Nasal Saline spray (2% buffered saline) or Neti Pot
- Effective Decongestant
- Also use as pretreatment prior to Intranasal Steroid
- Effective in recurrent Sinusitis when used daily
- Mucolytic
- Guaifenesin (e.g. Mucinex) 600 to 1200 mg PO bid
- Combination Mucolytic with Decongestant
- Entex PSE bid
- Topical Decongestants (Maximum of 3 days of use)
- Systemic Decongestants (e.g Pseudoephedrine)
- Not recommended due to systemic adverse effects and adds little to symptomatic relief over other options
- Diversion to Methamphetamine production only reinforces a policy to discourage pseudophedrine availability and use
- Consider 3 days of Afrin nasal spray for facial pain relief
- Intranasal Steroids (treat for 3-6 weeks minimum if indicated)
- Avoid Antihistamines
- Dry secretions
- Impede osteomeatal complex drainage
- Symptomatic relief
- Management: Antibiotics
- Indicated only in acute bacterial Sinusitis
- See Acute Sinusitis for Diagnosis
- See Sinusitis Prediction Rules
- Persistent Sinusitis symptoms >7-10 days
- Moderate to severe facial pain
- Fever over 101 F
- Protocol
- Antibiotic course
- Minimum course: 10 days
- Consider longer course for persistent or recurrent symptoms suggestive of bacterial Sinusitis: 14-28 days
- Change antibiotic if no improvement in 7 days
- Beta-lactamase resistance in acute cases: <30%
- Beta-lactamase resistance in chronic cases: 40-50%
- Antibiotic course
- First-Line
- Indications to start on first-line agents
- Mild to moderate symptoms
- No daycare exposure or recent antibiotic use
- Consider starting with high dose Amoxicillin if higher risk for Antibiotic Resistance
- Amoxicillin
- Adult: 1000 mg orally twice daily
- Child: 90 mg/kg/day divided bid to tid (high dose)
- Disadvantages: Misses Beta-lactamase producers
- Trimethoprim Sulfamethoxazole (Bactrim, Septra)
- No longer recommended as first-line agent
- Higher resistance rate than other agents
- Dosing
- Adult: 160 TMP and 800 SMZ bid
- Child: 8 mg/kg/day TMP,40 mg/kg/day SMZ div. bid
- Disadvantages
- Misses Staphylococcus
- Risk of Toxic Epidermal Necrolysis
- Risk of Steven's Johnson Syndrome
- No longer recommended as first-line agent
- Indications to start on first-line agents
- Second-Line
- Indications to start on second-line agents
- Severe symptoms
- Consider for daycare exposure or recent antibiotic use (or use high dose Amoxicillin instead)
- Amoxicillin-Clavulanate (Augmentin)
- Adult: 875 mg PO bid or 500 mg PO tid
- Child
- TID: 40 mg/kg/day divided q8 hours
- BID: 45 mg/kg/day divided q12 hours
- Cefuroxime (Zinacef, Ceftin)
- Adult: 250 to 500 mg PO bid
- Child: 30 mg/kg/day divided bid
- Cefpodoxime (Vantin)
- Adult: 200 mg PO bid
- Child: 10 mg/kg/day once daily
- Cefdinir (Omnicef)
- Adult: 300 mg PO bid or 600 mg PO qd
- Child: 14 mg/kg/day divided qd-bid
- Avoid Cefixime
- Poor Gram Positive Bacteria coverage
- Indications to start on second-line agents
- Third Line
- Consider adding Flagyl to second-line agents
- Consider second-line agent for longer course (4 week)
- Fluoroquinolones (avoid under age 16 years)
- Levofloxacin (Levaquin) 500 mg daily
- Moxifloxacin (Avelox) 400 mg daily
- Indicated only in acute bacterial Sinusitis
- Management: Penicillin or Cephalosporin Allergy
- Macrolide antibiotics (High bacterial resistance rate)
- Trimethoprim-Sulfamethoxazole (Bactrim, Septra)
- Increasing bacterial resistance
- Other agents are preferred for Sinusitis
- Clindamycin (Cleocin)
- Consider in combination with Rifampin if severe
- Poor efficacy against Gram Negative Bacteria
- Fluoroquinolones (avoid under age 16 years)
- See Third line agents above
- Management: Referral Indications to ENT
- See Also Sinus Surgery
- Sinusitis refractory to maximal medical management
- Recurrent Acute Sinusitis
- Persistent Chronic Sinusitis Symptoms
- Complicated Sinusitis
- Immunocompromised patient
- Toxic appearance
- Suspected contiguous orbital or cerebral involvement
- See red flag symptoms in Acute Sinusitis
- Sphenoid and Frontal Sinusitis are higher risk
- References
- (2000) Otolaryngol Head Neck Surg 123:S1-S31
- (2001) Pediatrics 108:A24
- Aring (2011) Am Fam Physician 83(9): 1057-63
- Brook (2000) Laryngol 109:2-20
- Dowell (1998) Am Fam Physician 58:1113-23
- Osguthorpe (2001) Am Fam Physician 63:69-76
- Poole (1999) Am J Med 106(5A):38S-47S
- Snow (2001) Ann Intern Med 134:495-7